中华肾脏病杂志
中華腎髒病雜誌
중화신장병잡지
2010年
9期
702-707
,共6页
周珍%吴小燕%姚涛%高苹%於文丽%杨国铭
週珍%吳小燕%姚濤%高蘋%於文麗%楊國銘
주진%오소연%요도%고평%어문려%양국명
糖尿病肾病%脂联素%趋化因子CCL2%脂联素受体
糖尿病腎病%脂聯素%趨化因子CCL2%脂聯素受體
당뇨병신병%지련소%추화인자CCL2%지련소수체
Diabetic nephropathies%Adiponectin%Chemokine CCL2%Adiponectin receptor
目的 探讨脂联素(ADPN)及其受体(AdipoR)对糖尿病肾病的保护作用及其可能机制.方法 (1)64只雌性SD大鼠被随机均分入对照组和实验组:实验组一次性空腹腹腔注射链脲菌素(STZ)60 mg/kg,诱导糖尿病大鼠模型;对照组腹腔注射等体积的枸橼酸缓冲液.于糖尿病大鼠成模后第2、6、10、12周两组分别测体质量、肾质量、空腹血糖、24 h尿白蛋白排泄量;心内采血检测空腹血清胰岛素;ELISA法检测血、尿脂联素浓度;取肾脏常规制作PAS染色,免疫组化SP法检测肾脏脂联素受体1和2(AdipoR1和AdipoR2)的表达.(2)将NRK-52E细胞分别用含5 mmol/L葡萄糖(正常对照组)、30 mmol/L葡葡糖(高糖组)、30mmol/L葡萄糖+不同浓度ADPN(终浓度分别为1 mg/L、5 mg/L、10 mg/L)培养,12 h后RT-PCR法检测单核细胞趋化蛋白1(MCP-1)mRNA表达.结果 (1)造模成功后6、10、12周实验组血清和尿ADPN水平均高于对照组(P<0.01),并随着肾脏病变进展而逐渐升高.(2)实验组各时期AdipoR1和AdipoR2在肾脏的表达高于对照组,并随时间逐渐增强,其与血清脂联素水平呈正相关(r=0.666,P<0.01;r=0.684,P<0.01).(3)MCP-1 mRNA在高糖组表达较高,加入脂联素以后MCP-1 mRNA表达显著减少(P<0.05).结论 血和尿脂联素水平随糖尿病肾病病程进展而升高,与AdipoR1和AdipoR2的表达亦呈正相关,推测脂联素通过AdipoR直接作用于肾小管,通过减少MCP-1的表达对肾脏起保护作用.
目的 探討脂聯素(ADPN)及其受體(AdipoR)對糖尿病腎病的保護作用及其可能機製.方法 (1)64隻雌性SD大鼠被隨機均分入對照組和實驗組:實驗組一次性空腹腹腔註射鏈脲菌素(STZ)60 mg/kg,誘導糖尿病大鼠模型;對照組腹腔註射等體積的枸櫞痠緩遲液.于糖尿病大鼠成模後第2、6、10、12週兩組分彆測體質量、腎質量、空腹血糖、24 h尿白蛋白排洩量;心內採血檢測空腹血清胰島素;ELISA法檢測血、尿脂聯素濃度;取腎髒常規製作PAS染色,免疫組化SP法檢測腎髒脂聯素受體1和2(AdipoR1和AdipoR2)的錶達.(2)將NRK-52E細胞分彆用含5 mmol/L葡萄糖(正常對照組)、30 mmol/L葡葡糖(高糖組)、30mmol/L葡萄糖+不同濃度ADPN(終濃度分彆為1 mg/L、5 mg/L、10 mg/L)培養,12 h後RT-PCR法檢測單覈細胞趨化蛋白1(MCP-1)mRNA錶達.結果 (1)造模成功後6、10、12週實驗組血清和尿ADPN水平均高于對照組(P<0.01),併隨著腎髒病變進展而逐漸升高.(2)實驗組各時期AdipoR1和AdipoR2在腎髒的錶達高于對照組,併隨時間逐漸增彊,其與血清脂聯素水平呈正相關(r=0.666,P<0.01;r=0.684,P<0.01).(3)MCP-1 mRNA在高糖組錶達較高,加入脂聯素以後MCP-1 mRNA錶達顯著減少(P<0.05).結論 血和尿脂聯素水平隨糖尿病腎病病程進展而升高,與AdipoR1和AdipoR2的錶達亦呈正相關,推測脂聯素通過AdipoR直接作用于腎小管,通過減少MCP-1的錶達對腎髒起保護作用.
목적 탐토지련소(ADPN)급기수체(AdipoR)대당뇨병신병적보호작용급기가능궤제.방법 (1)64지자성SD대서피수궤균분입대조조화실험조:실험조일차성공복복강주사련뇨균소(STZ)60 mg/kg,유도당뇨병대서모형;대조조복강주사등체적적구연산완충액.우당뇨병대서성모후제2、6、10、12주량조분별측체질량、신질량、공복혈당、24 h뇨백단백배설량;심내채혈검측공복혈청이도소;ELISA법검측혈、뇨지련소농도;취신장상규제작PAS염색,면역조화SP법검측신장지련소수체1화2(AdipoR1화AdipoR2)적표체.(2)장NRK-52E세포분별용함5 mmol/L포도당(정상대조조)、30 mmol/L포포당(고당조)、30mmol/L포도당+불동농도ADPN(종농도분별위1 mg/L、5 mg/L、10 mg/L)배양,12 h후RT-PCR법검측단핵세포추화단백1(MCP-1)mRNA표체.결과 (1)조모성공후6、10、12주실험조혈청화뇨ADPN수평균고우대조조(P<0.01),병수착신장병변진전이축점승고.(2)실험조각시기AdipoR1화AdipoR2재신장적표체고우대조조,병수시간축점증강,기여혈청지련소수평정정상관(r=0.666,P<0.01;r=0.684,P<0.01).(3)MCP-1 mRNA재고당조표체교고,가입지련소이후MCP-1 mRNA표체현저감소(P<0.05).결론 혈화뇨지련소수평수당뇨병신병병정진전이승고,여AdipoR1화AdipoR2적표체역정정상관,추측지련소통과AdipoR직접작용우신소관,통과감소MCP-1적표체대신장기보호작용.
Objective To investigate the protective effect and possible mechanism of adiponectin (ADPN) and its receptors in diabetic nephropathy (DN). Methods A total of 64 Sprague-Dawley female rats were equally divided into diabetes mellitus (DM) group with streptozotocin(STZ) 60 mg/kg injection, and normal control (NC) group with the same dose of citric acid buffer randomly. At the end of 2, 6, 10 and 12 weeks, weight, fast blood glucose, 24-hour urinary albumin excretion, serum creatinine and serum fast blood insulin were measured. The level of adiponectin in urine and serum was examined by ELISA. The pathological change of kidney tissue was studied by periodic acid-Schiff's staining (PAS) and the expression of adiponectin receptor 1 (adipoR1), adiponectin receptor 2 (adipoR2) was determined by immunohistochemistry.The NRK-52E cells were cultured with 5 mmol/L glucose (control group), 30 mmol/L glucose (high glucose group), 30 mmol/L glucose+different concentrations of adiponectin (1 mg/L, 5 mg/L, 10 mg/L, ADPN groups), respectively. The mRNA expression of monocyte chemoattractant protein 1 (MCP-1) was measured by RT-PCR after 12 h. Results (1)Both in urine and serum, the levels of ADPN in DM group were higher than that in NC group after 6 weeks (P<0.01) and increased gradually during the whole experiment. (2)Compared with NC group, the expressions of AdipoR1 and AdipoR2 in kidney tissues were elevated gradually in DM group. There was a significant positive correlation of ADPN with AdipoR1 and AdipoR2 in DM group(r=0.666, P<0.01;r= 0.684, P<0.01). (3)The expression of MCP-1 increased in high glucose group, but decreased in 1 mg/L, 5 mg/L, 10 mg/L adiponectin group. Conclusions The level of ADPN in urine and serum is positively correlated with its receptors and elevates with the process of diabetic kidney disease. High level of serum adiponectin plays a protective role through the direct action of AdipoR and the alleviation of MCP-1 expression in renal tubules.